Free Trial

Cabaletta Bio (CABA) Competitors

Cabaletta Bio logo
$1.59 -0.03 (-1.85%)
Closing price 08/25/2025 04:00 PM Eastern
Extended Trading
$1.58 -0.02 (-0.94%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CABA vs. XNCR, ANAB, PVLA, ARVN, SAGE, ORKA, SVRA, GOSS, RAPP, and SEPN

Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Xencor (XNCR), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), Arvinas (ARVN), Sage Therapeutics (SAGE), Oruka Therapeutics (ORKA), Savara (SVRA), Gossamer Bio (GOSS), Rapport Therapeutics (RAPP), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

Cabaletta Bio vs. Its Competitors

Cabaletta Bio (NASDAQ:CABA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Cabaletta Bio currently has a consensus price target of $14.43, indicating a potential upside of 807.46%. Xencor has a consensus price target of $23.71, indicating a potential upside of 196.06%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Cabaletta Bio is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cabaletta Bio
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00
Xencor
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

Cabaletta Bio has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Cabaletta Bio has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A-$115.86M-$2.71-0.59
Xencor$110.49M5.17-$232.62M-$2.40-3.34

Cabaletta Bio has a net margin of 0.00% compared to Xencor's net margin of -121.52%. Xencor's return on equity of -25.75% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Cabaletta BioN/A -92.11% -74.08%
Xencor -121.52%-25.75%-18.19%

In the previous week, Xencor had 8 more articles in the media than Cabaletta Bio. MarketBeat recorded 8 mentions for Xencor and 0 mentions for Cabaletta Bio. Xencor's average media sentiment score of 0.54 beat Cabaletta Bio's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company Overall Sentiment
Cabaletta Bio Neutral
Xencor Positive

Summary

Cabaletta Bio and Xencor tied by winning 7 of the 14 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CABA vs. The Competition

MetricCabaletta BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$148.17M$3.12B$5.82B$9.74B
Dividend YieldN/A2.24%4.40%4.08%
P/E Ratio-0.5920.7730.1625.84
Price / SalesN/A345.85432.33103.25
Price / CashN/A43.2325.7828.79
Price / Book0.519.649.525.99
Net Income-$115.86M-$54.08M$3.27B$265.29M
7 Day Performance-1.85%3.85%3.17%3.87%
1 Month Performance-4.22%2.54%3.11%0.75%
1 Year Performance-73.37%6.59%31.47%18.20%

Cabaletta Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CABA
Cabaletta Bio
2.0463 of 5 stars
$1.59
-1.9%
$14.43
+807.5%
-73.8%$148.17MN/A-0.5950
XNCR
Xencor
3.6612 of 5 stars
$8.01
-4.8%
$23.71
+196.1%
-54.7%$571.30M$146.93M-3.34280
ANAB
AnaptysBio
2.9621 of 5 stars
$20.10
-0.6%
$46.13
+129.5%
-46.8%$562.74M$123.16M-4.49100
PVLA
Palvella Therapeutics
2.9204 of 5 stars
$50.13
-6.2%
$58.50
+16.7%
N/A$554.44M$42.81M-4.14N/A
ARVN
Arvinas
3.9991 of 5 stars
$7.48
+2.2%
$19.76
+164.2%
-71.4%$549.17M$372.80M-7.41420Positive News
SAGE
Sage Therapeutics
3.3744 of 5 stars
$8.68
flat
$7.85
-9.6%
N/A$543.54M$41.24M-1.78690
ORKA
Oruka Therapeutics
2.2799 of 5 stars
$14.51
-6.0%
$40.38
+178.3%
N/A$543.41MN/A-5.16N/A
SVRA
Savara
3.2526 of 5 stars
$3.14
-0.6%
$6.17
+96.4%
-28.1%$542.72MN/A-6.2820
GOSS
Gossamer Bio
3.244 of 5 stars
$2.36
+0.9%
$8.50
+260.2%
+159.7%$536.62M$114.70M-3.81180
RAPP
Rapport Therapeutics
1.8961 of 5 stars
$14.63
-0.9%
$29.50
+101.6%
-34.4%$534.00MN/A-5.85N/A
SEPN
Septerna
1.6931 of 5 stars
$11.96
-0.3%
$26.75
+123.7%
N/A$533.18M$1.08M-1.19N/A

Related Companies and Tools


This page (NASDAQ:CABA) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners